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Background. Systemic sclerosis (SSc) is a multisystem disease characterized by cutaneous and visceral fibrosis. Face and mouth
changes include telangiectasia, sicca syndrome, and thinning and reduction of mouth width (microcheilia) and opening
(microstomia). We applied autologous fat transplantation compared with autologous adipose-derived stromal cells (ADSCs)
injection to evaluate the clinical improvement of mouth opening.Methods. From February toMay 2013 ten consecutive SSc patients
were enrolled from the outpatient clinic of Plastic Surgery Department of Sapienza University of Rome. Patients were divided into
two groups as follows: 5 patients were treated with fat transplantation and 5 patients received infiltration of ADSCs produced by
cell factory of our institution. To value mouth opening, we use the Italian version of Mouth Handicap in Systemic Sclerosis Scale
(IvMHISS). Mouth opening was assessed in centimetres (Maximal Mouth Opening, MMO). In order to evaluate compliance and
physician and patient satisfaction, we employed a Questionnaire of Satisfaction and the Visual Analogic Scale (VAS) performed
before starting study and 1 year after the last treatment.Results andConclusion.We noticed that both procedures obtained significant
results but neither one emerged as a first-choice technique. The present clinical experimentation should be regarded as a starting
point for further experimental research and clinical trials.
1. Introduction
Systemic sclerosis (SSc) or scleroderma is a multisystem
disease characterized by cutaneous and visceral fibrosis. After
an initial period of induration, dermis and visceral become
infiltrated with collagen and become both harder and thicker.
It is an autoimmune disease with a prevalence of 2-3 per
10.000 people. The ratio of women to men is 4 to 1, the
majority diagnosed between the age of 30 and 50 [1].
Cutaneous manifestations of this disease are very plain
and hard to conceal. Limited range of mouth opening, along
with other symptoms such as dry mouth, can lead to difficul-
ties with oral hygiene and eating. Facial involvement and oral
complications are typical features of SSc, leading to aesthetic
changes and impairment of the patient’s self-image. The face
becomes amimic, cutaneous wrinkles disappear around the
mouth, vertical furrows develop, and the nose becomes
sharp. Face and mouth changes also include telangiectasia,
sicca syndrome, and thinning and reduction of mouth width
(microcheilia) and opening (microstomia), also favoured by
osteolysis of mandibular angles and by fibrosis of soft tissues.
Sclerosis of the extremities is highly disabling and results
in significant dysfunction; the facial symptoms bear cosmetic
disfigurement and limit expression, leading to a mask-like
stiffness of the face. Currently, therapy is limited and no
antifibrotic treatment has proven its efficacy. Recent studies
have assessed different biological agents for the treatment
of skin thickness as neutralizing antibodies, tyrosine kinase
inhibitors, proteins with antifibrotic properties, or proteins
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that induce immune tolerance, generally well tolerated but
not showing significant efficacy [2].
Over the years, autologous fat transplantation has become
the first-choice technique to hide cutaneous lesions; this
approach, using the patient’s own body fat as a natural
filler to achieve structural modifications, takes advantage
of its abundance and accessibility and avoids complications
associated with foreign materials. Elective liposuction for
fat transplantation is nowadays considered a safe and well-
tolerated procedure [3, 4].
Recently, a stem cell population within the adipose
stromal compartment has been identified, termed adipose-
derived stromal cells (ADSCs). This stem cell reservoir can
be easily obtained from a very small amount of liposuction
aspirates (1–5 cc), since it is present in any type of white
adipose tissue [5]. Moreover, ADSCs possess the ability to
differentiate into various cell types, including adipocytes,
chondrocytes, osteoblasts, myocytes, and neurons under
specific differentiation conditions. Some studies describe the
potential use of ADSCs in treating some autoimmune and
inflammatory disorders, such as type I diabetes mellitus,
systemic sclerosis and systemic lupus erythematosus, myas-
thenia gravis, and multiple sclerosis [6–8].
In this project, we applied the procedure of autologous fat
transplantation compared with autologous ADSCs injection
to evaluate the clinical improvement of mouth opening.
2. Materials and Methods
From February to May 2013, ten consecutive SSc patients
(8 female and 2 male), fulfilling American College of
Rheumatology (ACR) criteria and classified as having diffuse
cutaneous scleroderma [9], were enrolled from the outpatient
clinic of the Department of Plastic Surgery of Sapienza
University of Rome and agreed by a written informed
consent to participate in the study, which was approved by
our ethics committee (Ref. 1834/25.03.10) and conducted in
full accordance with ethical principles, including the World
Medical Association Declaration of Helsinki.
These patients had advanced systemic sclerosis-related
perioral thickening andmouth opening limitation.The group
was homogeneous for age (age range: 20–48 years), disease
state, and duration and finally for clinical characteristics.
At each visit, personal, anamnestic, and objective (clinical
characteristics) data were collected and recorded, using a
written form that was held securely, thus being accessible only
to study investigators (Table 1).
Inclusion criteria called for signs of no active disease
expressed by increasing size of lesions, appearance of new
lesions, and/or clinical signs of inflammation within the last
6 months.
Exclusion criteria were as follows: pregnancy or lacta-
tion, any immunomodulating or immunosuppressive therapy
within the last 4 weeks and any topical therapy within the last
2 weeks except for the use of emollients, and finally patient’s
refusal to participate in the study.
Patients were divided into two groups as follows: 5
patients were treated with fat transplantation “group L”
Table 1: Patients’ characteristics: A: patients treated with ADSCs
injection and L: patients treated with fat transplantation.
Patients Age Disease status Diseaseduration
Localized
scleroderma
1 A 23 1-year diseasestabilization 3 years Face and hands
2 A 25 9-year diseasestabilization 5 years Face
3 A 35 6-year diseasestabilization 10 years Face
4 A 38 6-year diseasestabilization 10 years Face
5 A 39 15-year diseasestabilization 13 years Face and hands
1 L 24 5-year diseasestabilization 3 years Face and hands
2 L 25 8-year diseasestabilization 3 years Face and hands
3 L 36 16-year diseasestabilization 12 years Face
4 L 39 8-year diseasestabilization 15 years Face
5 L 48 6-year diseasestabilization 18 years Face and hands
(lipofilling) and 5 patients received infiltration of ADSCs pro-
duced by cell factory of our institution “group A” (ADSCs).
The patients did not receive any remuneration for their
inclusion or treatment in this study.
After the first treatment, all patients underwent the same
procedure 3 months later. Follow-up was at 1 week, 1 month,
and 1 year. During the follow-up, it was possible to compare
our obtained results by using fat transplantation with ADSCs
infiltration.
2.1. Disability Evaluation. We want to describe several
parameters used to value disability often experienced by
scleroderma patients. Various modalities can be used to
measure the extent and severity of skin involvement. The
modified Rodnan Skin Score (MRSS), a summation of phys-
ical examination ratings over 17 skin sites (fingers, hands,
forearms, arms, face, chest abdomen, thighs, lower legs, and
feet), has become the standard primary outcome measure of
skin involvement during clinical trials and in practice [10].
MRSS is the current gold standard measure of skin
disease, but other methods that are more objective, precise,
and reproducible have been developed to assess skin involve-
ment. These include skin biopsy, ultrasonography, electronic
tonometry, cytometry, and durometry [11–16].
There are also different scales to value quality of life:
the Health-Related Quality of Life (HRQoL), the Health
Assessment Questionnaire (HAQ), and scleroderma HAQ
(sHAQ).This latter is more specific for SSc, as it adds to HAQ
5 visual analogue scales, evaluating Raynaud’s phenomenon,
digital ulcers, gastrointestinal and lung symptoms, and over-
all disease severity [17–19].
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Table 2: Italian version of Mouth Handicap in Systemic Sclerosis Scale (IvMHISS) assesses the handicap with mouth disability in SSc. It
consists of 12 items (each scored 0–4): 0 Never (Mai); 1 Rarely (Raramente); 2 Occasionally (Occasionalmente); 3 Often (Spesso); 4 Always
(sempre).
1 I have difficulties opening my mouthHo difficolta` ad aprire la bocca 0 1 2 3 4
2 I have to avoid certain drinks (sparkling, alcohol, etc.)Devo evitare alcuni tipi di bevande (frizzanti, alcoliche, ecc) 0 1 2 3 4
3 I have difficulties chewingHo difficolta` a masticare 0 1 2 3 4
4 My dentist has difficulties taking care of my teethIl mio dentist ha difficolta` a prendersi cura dei miei denti 0 1 2 3 4
5 My dentition had become alteredLa mia dentatura si e` alterata 0 1 2 3 4
6 My lips are retracted and/or my checks are sunkenLe mie labbra sono retratte e/o le mie guance sono infossate 0 1 2 3 4
7 My mouth is dryLa mia bocca e` secca 0 1 2 3 4
8 I have to drink oftenDevo bere spesso 0 1 2 3 4
9 My meals consist of what I can eat and not what I would like to eatDevo mangiare le cose che posso e non quelle che vorrei 0 1 2 3 4
10 I have difficulties speaking clearlyHo difficolta` a parlare con chiarezza 0 1 2 3 4
11 The appearance of my face is modifiedL’aspetto della mia faccia si e` modificato 0 1 2 3 4
12 I have trouble with the way my face looksL’aspetto della mia faccia mi crea problemi 0 1 2 3 4
Hand disability can be studied by specific instruments,
such as Cochin Hand Function Scale (CHFS) and Hand
Mobility in Scleroderma Scale (HAMIS) [20, 21].
In our study, we decided to examine the following param-
eters. Skin tightening due to subcutaneous and ligamentous
collagen deposit associated with diffuse systemic sclerosis
results in a mechanical inability to open the mouth. To value
the mouth disability we use the Italian version of Mouth
Handicap in Systemic Sclerosis Scale (IvMHISS).
MHISS assessing the handicap with mouth disability in
SSc consists of 12 items (each scored 0–4) with a total score
range from 0 to 48 (Table 2) [22–27].
Mouth opening was assessed in centimetres (Maximal
Mouth Opening, MMO) by measuring the distance between
the tips of upper and lower right incisive teeth (mean of two
consecutive measurements).
The patients were asked to fill in a questionnaire in
which their degree of satisfaction could be expressed by
the following ratings: unsatisfied, moderately satisfied, rather
satisfied, and very satisfied.
In order to assess compliance and physician and patient
satisfaction we employed an evaluation system according to
the Visual Analogic Scale (VAS) giving a score ranging from
1 up to 10, where 1 indicates no improvement and 10 indicates
the maximum possible improvement.
IvMHISS, MMO, Questionnaire of Satisfaction, and VAS
were performed before starting study and 1 year after the last
treatment.
Figure 1: A 39-year-old woman withmicrostomia before treatment.
2.2. Case Report 1
Patient: A 39-Year-Old Woman. She first reported the onset
of the disease at the age of 25. Disease was characterized
by slow but progressive symmetrical skin thickening limited
to the fingers (sclerodactyly) and to the face (especially
microstomia). She reported that for 18 years the disease was
stable (Figure 1). The patient underwent fat transplantation
(Figures 2 and 3).
2.3. Case Report 2
Patient: A 38-Year-Old Woman. She reported the disease
onset at 28 years of age. Disease was characterized by fast
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Figure 2: Autologous fat transplantation.
Figure 3: Follow-up at 1 year.
symmetrical skin thickening limited to either the fingers
(sclerodactyly) or to the face (especially microstomia). She
also reported that for 16 years the disease has not progressed
(Figure 4). The patient underwent ADSCs infiltration (Fig-
ures 5 and 6).
2.4. Technique
2.4.1. Autologous Fat Transplantation Procedure. Theperium-
bilical abdominal region represented the donor site for all
patients. After the administration of local modified Klein
solution, 1 liter of sodium chloride 0.9%, 20mL of lidocaine
2%, and 1mL of epinephrine 1 : 200,000, adipose tissue
was harvested using hand-generated suction by means of
a one-hole blunt 3mm cannula attached to a 10 cc Luer-
lock syringe. Such nontraumatic low-negative pressure drain
method preserves adipocytes intact and viable for transfer
[28].
A total amount of 40mL of lipoaspirate was harvested
from the abdomen.Afterward, it was decanted 15minutes and
only the layer containing adipocytes was used for fat injec-
tion.The fat infiltrationwas performedusing a blunt injection
cannula of 2mm in diameter. Perioral region was injected
using many radiating passages at the subcutaneous level for
a total of 16mL. The cannula was inserted in 4 symmetric
Figure 4: A 38-year-oldwomanwithmicrostomia before treatment.
Figure 5: ADSCs injection.
Figure 6: Follow-up at 1 year.
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sites: 2 located just upon and 2 just below labial commissures.
Antibiotics were given to all patients as a precautionary
measure.
The selected areas for fat injection were six. Three were at
the level of upper perioral region: two at the level of nasolabial
fold (injected fat amount: 2mL for each side) and one at the
level of the upper lip (in which we injected 2mL from the
right side of the upper lip to the center and 2mL from the
left side of the upper lip to the center, both at the level of
vermilion border). The other three selected areas were in the
lower perioral region: two at the level of a line extending from
the labial commissure towardmandibular border (injected fat
amount: 2mL for each side) and one at the level of the lower
lip (in which we injected 2mL from the right side of the lower
lip to the center and 2mL from the left side of the lower lip to
the center).
2.4.2. ADSCs Isolation, Expansion (StandardCultureMethod),
and Injection. A total amount of 20mL of lipoaspirate was
harvested from the abdomen with the same technique of
fat transplantation. Lipoaspirate was sent to the laboratory
for cell cultivation within 1 hour and processed for ADSCs
isolation.
Primary cultures of ADSCs derived from each sclero-
derma patient were expanded following the guidelines of
current GMP. On the day of transplantation, cells were
detached with 0.5mMEDTA/0.05% trypsin for 5min at 37∘C
and counted. Then, ADSCs were centrifuged at 1,500 rpm
for 10min, washed twice in PBS to remove serum, and
finally resuspended in an adequate volume of synthetic
stabilized HA solution (a 1.6% solution of synthetic HA,
without chemical modifications and with a molecular weight
of 1 × 103 KDa, very similar to the endogenous HA) at a
standard concentration of 8 × 105 cells/mL. After gentle
mixing, the suspension was kept under ambient conditions
for 10–15min to allow cell adherence to the hyaluronan
matrix. Homogeneous dispersion of the cells within the gel
was ensured by microscopical observation. Then, the cell
supplemented HA solution was loaded into an injection
syringe and carried to the operating room [29].
Usually after 3 weeks the patient went back to the oper-
ating room for the injection of the expanded ADSCs. This
procedure did not require anaesthesia; only one patient asked
for blunt sedation to calm down. The injection technique
relied on preoperative topographic markings. Small aliquots
of cell-enriched HA were infiltrated in the chosen areas.
The infiltration was done using 2mL syringes provided
with a 30-gauge 1/2 needle. We employed always 4mL of
hyaluronic acid for each patient, keeping a constant rate of
8 × 105 expanded ADSCs for each mL of HA.
Small aliquots of cell transferred by hyaluronic acid
were infiltrated at the subcutaneous level of selected perioral
regions: six areas, two in the upper lip and two in the lower
lip (two lateral for each lip), plus one area for each opposite
mouth corner region.
Table 3: Maximal Mouth Opening (MMO) by measuring the
distance between the tips of upper and lower right incisive teeth.
Patients Pretreatment (T0)opening mouth (cm)
Posttreatment
opening mouth (cm)
1 L 3.6 4.2
2 L 3.4 3.8
3 L 2.6 3.4
4 L 3.1 3.8
5 L 3.3 4.2
1 A 3.4 4.4
2 A 2.5 3.1
3 A 3.3 3.7
4 A 2.9 3.6
5 A 3.2 4.0
Figure 7: A 48-year-old woman before treatment.
3. Results
All patients treated presented a favourable outcome with
improvement in subjective wellness of the skin in the perioral
areas.
Both procedures improved the scores of IvMHISS scale at
T1 versus T0. A significant score increase was shown in group
L (𝑝 value 0.0234; 𝑡: 2.7940) and in groupA (𝑝 value 0.0022; 𝑡:
4.4453); instead there was no statistical significant difference
in improvement between groups L and A (𝑝 value 0.9619; 𝑡:
0.0485).
Maximal Mouth Opening, assessed as interincisor dis-
tance (Figures 7 and 8), was assessed by the same operator at
baseline (T0) and after 1-year follow-up (T1). Patients of both
groups benefited from the treatments for mouth opening
(Table 3). A significant increase ofmouth opening was shown
in group L (𝑝 value 0.0171; 𝑡: 2.9994) and in group A (𝑝
value 0.0322; 𝑡: 2.5873); instead the difference of improvement
between groups L andAwas statistically insignificant (𝑝 value
0.5833; 𝑡: 0.5587).
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Figure 8: Aesthetic changes in the perioral region after autologous
fat transplantation.
Table 4: Visual Analogic Scale (VAS). Score ranging from 1 to 10,
whereby 1 indicates no improvement and 10 the maximum possible
improvement.
Patients VAS
1 L 6
2 L 5
3 L 6
4 L 7
5 L 8
1 A 7
2 A 8
3 A 8
4 A 8
5 A 8
When the patients were asked to express their overall
personal opinion on the procedure they had undergone and
its effectiveness, 80% (4/5) and 20% (1/5) in group L claimed
to be rather satisfied and very satisfied, respectively. In group
A, 20% (1/5) and 80% (4/5) claimed to be rather satisfied and
very satisfied, respectively.
High values of VAS scale were obtained in both groups
as shown in Table 4; instead the difference between groups L
and A in terms of improvement was statistically insignificant
(𝑝 value 0.0339; 𝑡: 2.5560) (i.e., we obtained improvement in
groups A and L with both techniques, without any significant
difference between patients treated with Lipofilling with
respect to patients treated with ADSCs).
4. Discussion
SSc has an important social and emotional impact [30]. It is
associatedwith increased functional impairment, body image
distress due to skin lesions, and psychosocial comorbidity,
particularly depression. Prevalence of depressive symptoms
in SSc patients ranges from 36% to 65% and contributes to
the worsening of any aspect of the disease [31].
Scleroderma patients report problems across multiple
domains including fatigue, pain disability, sleep, interper-
sonal functioning, anxiety, and more generally physical and
mental-health-related quality of life [30].
Fear of the disease (anxiety/panic) and depression are
often not revealed by the patient because of the embarrass-
ment of discovering an emotional illness. Scleroderma can
be disfiguring and patients’ psychosocial well-being is often
affected more by disfigurement caused by facial changes.
Low self-esteem alters social interactions and intimate rela-
tionships. The disease causes disability and may disrupt
patients’ ability to perform daily activities. Patients with
mouth opening impairment cannot eat solid food, drink, and
take care of their teeth thus highly limiting their social role in
life.
Therapeutic strategies available today for chronic inflam-
matory diseases, such as SSc, often represent a way to obtain
symptoms relief.
Au et al. [2] evaluated changes in vascular and mus-
culoskeletal involvement in patients with interstitial lung
disease comparing placebo treatment with oral cyclophos-
phamide (CYC). Authors demonstrated that there were no
differences in dermal ulcer and musculoskeletal measures
between the CYC and placebo groups at baseline and 24
months. Instead, mean oral aperture improved over time in
the study participants.
Therapeutic repair encompasses the converging triad
of rejuvenation, regeneration, and replacement strategies,
which rely on self-healing processes, stem cell regeneration,
and/or organ transplantation. Transplant medicine exploits
the replacement strategy as a valuable option to recycle
used parts and restore failing organ function by means
of exogenous substitutes. It is, however, limited by donor
shortage. Stem cell-based regeneration offers the next frontier
of medical therapy through delivery of essentially unlimited
pools of autologous progenitor cells to achieve structural and
functional repair [32, 33].
However, translation into clinical applications requires
the establishment of a regenerative medicine community
of practice capable of bridging discovery with personalized
treatment solutions. Indeed, this multidisciplinary special-
ized workforce will be capable of integrating the new science
of embryology, immunology, and stem cell biology into
bioinformatics and network medicine platforms, ensuring
implementation of therapeutic repair strategies into individ-
ualized disease management algorithms.
Advanced cell-based therapies provide promising ther-
apeutic possibilities to enhance repair or regeneration of
damaged tissues also because their development may be
greatly facilitated by the availability of an easily accessible and
reproducible cell source.
In recent years, there has been growing emphasis on the
use of mesenchymal stem cells (MSCs) for advanced cell
therapy, due to their ability to be expanded in culture and to
differentiate into multiple cell types. It is well established that
MSCs secrete a broad spectrum of bioactive molecules with
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immunoregulatory and/or regenerative activities. Through
direct cell-cell interaction or the secretion of various factors,
MSCs can exert a great effect on local tissue repair by mod-
ulating the local environment and activating endogenous
progenitor cells. Taken together, these properties makeMSCs
promising candidates for cell therapy in various diseases.
In particular, adipose-derived stem cells (ADSCs), iso-
lated from stromal vascular fraction, are able to differ-
entiate into various cell lineages such as chondrocytes,
osteoblasts, and adipocytes and to exert potent immunomod-
ulatory, proangiogenic, antiapoptotic, antifibrotic, and anti-
inflammatory effects important in preventing tissue degener-
ation. In particular, ADSCs’ angiogenic and immunomodula-
tory properties, including a suppressive response on collagen-
reactive T cells and the capacity to restore immune tolerance
by inhibiting the inflammatory response in vivo, strongly
suggest their use for chronic pathologies, especially for
autoimmune and inflammatory disorders [34].
Whilst a set of clinical trials are demonstrating safety and
efficacy of personalized cell-based treatments using ADSCs,
translation to patients is faced by an obstacle: the heterogene-
ity in 13 treatment methods. Standardizing and automating
the manufacturing and characterization of ADSCs allows
better comparisons and identification of optimal treatments.
Moreover, cell-based techniques are costly, as cells need
to be sent to centralized cell factories for cell expansion.
Cell factories often are multipurpose (supporting numerous
different therapies), utilize capital-intensive clean rooms and
equipment, and need highly qualified personnel to imple-
ment manual processes. Transport of biological materials to
and fromcentralized cell factories poses additional regulatory
problems.
In fact, despite the advantages of cell-based approaches,
in terms of both effectiveness and therapeutic potential, the
diffusion of such therapies is still limited by the high costs of
manufacturing processes and qualified personnel, as well as
by the stringent rules that govern the isolation and expansion
of cells for therapeutic use (GMP requirements).
Because of the above discussed limitations, it was nec-
essary to turn back to another well-established technique
exploiting ADSCs’ potentialities as fat transplantation.
Over the years, autologous fat transplantation or “lipofill-
ing technique” has become the first-choice procedure to fill
depressed areas, restore anatomical saliences, and correct
contour deformities or volumetric defects [3, 4].
Fat is ubiquitous and easily obtainable in large quantity
with a minimal invasive collection procedure, limited patient
discomfort, and minimal ethical considerations: it may be
injected safely and efficaciously.
After harvesting fat, it must be processed in order to limit
the blood or oil within the lipoaspirates so that only pure fat
will be used for injection.
There are many different ways to process fat after its
collection. Many authors described sedimentation by gravity
or decantation, filtering, and centrifugation [35–38].
Currently, there is no agreement among authors in terms
of which is the best method for processing fat grafts. In
our study, we used decantation for a personal preference; in
fact, we noticed that fat processed through decantation is
more fluid and so more useful for scleroderma patients who
present very fibrous areas, where the access and treatment
are difficult. Many experimental studies designed to compare
these 3 techniques were evaluated and the debate continues
as to which is the best.
5. Conclusion
In this project, based on the successful results of our pre-
vious pilot study on cutaneous manifestations of systemic
sclerosis (SSc) [39], we aim to compare twomethods, ADSCs
infiltration and fat transplantation, to evaluate their potential
in treating diseases with few or no therapeutic choices.
Such personalized therapies allow each patient to represent
a resource for the treatment of his/her pathology.
ADSCs infiltration is an advanced method that is not
performed by many laboratories in Italy. There are several
intermediate and critical substeps required for effective cell
manipulation and the entire process must comply with strict
regulations. It is a procedure particularly useful in cases
where not even the insertion of the smallest diameter cannula
is possible, such as skin fibrosis. The main disadvantage is
represented by its high costs due to cell preparation in specific
laboratories and because it is performed in two separate
sessions, thus increasing patient discomfort.
Autologous decanted fat transplantation allows us to
obtain satisfactory results in terms of tissue trophism and
mouth opening improvement, taking advantage of adipose-
derived stromal cells properties and exploiting the fluidity
of fat obtained from fat decantation especially to treat very
fibrotic areas. Compared to the ADSCs injection, its main
disadvantage is represented by cannula use, which is more
traumatic with respect to thin needle employment. Cannula
use also requires access sites, which are sutured possibly lead-
ing to scars. Fat adsorption is unpredictable andmay result in
irregularities and asymmetries with respect to more precise
ADSCs injection. On the other hand, fat transplantation is a
more economic procedure, requiring only one surgical step
and one-day hospitalization.
In our study, we compared two techniques to determine
whether one prevailed in terms of results and patient satis-
faction.We noticed that both procedures obtained significant
results but neither one emerged as a first-choice method.
We strongly believe in fat potentialities especially in treat-
ing immune-mediated chronic diseases as scleroderma and
we hope to contribute to studies aimed at standardizing fat
use.The present clinical experimentation should be regarded
as a starting point for further experimental research and
clinical trials.
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